Zacks Research Raises Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research upped their FY2026 earnings per share estimates for Globus Medical in a research report issued to clients and investors on Friday, May 22nd. Zacks Research analyst Team now anticipates that the medical device company will post earnings per share of $4.73 for the year, up from their previous forecast of $4.40. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2027 earnings at $1.23 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

Several other analysts also recently issued reports on the company. Wells Fargo & Company decreased their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Needham & Company LLC lifted their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Barclays lifted their target price on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. TD Cowen raised Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Trading Up 0.3%

Shares of GMED opened at $85.10 on Wednesday. The business’s 50 day moving average is $87.27 and its 200 day moving average is $88.32. The company has a market capitalization of $11.55 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 1.75 and a beta of 1.00. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40.

Institutional Investors Weigh In On Globus Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its position in Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares in the last quarter. Invesco Ltd. raised its position in Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares in the last quarter. Bank of Montreal Can raised its position in Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after purchasing an additional 3,351,380 shares in the last quarter. Sculptor Capital LP grew its holdings in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after acquiring an additional 58,000 shares in the last quarter. Finally, William Blair Investment Management LLC grew its holdings in Globus Medical by 17.2% during the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after acquiring an additional 414,134 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.